Background Dupilumab, a fully human monoclonal antibody that blocks interleukin-4 and
interleukin-13, has shown efficacy in patients with asthma and elevated eosinophil levels. The …

Respiratory failure is the leading cause of death in patients with severe SARS-CoV-2
infection 1 , 2 , but the host response at the lung tissue level is poorly understood. Here we …

The cellular heterogeneity of the brain confounds efforts to elucidate the biological properties
of distinct neuronal populations. Using bacterial artificial chromosome (BAC) transgenic …

BACKGROUND: Atopic dermatitis (AD) is a common disease with an increasing prevalence.
The primary pathogenesis of the disease is still elusive, resulting in the lack of specific …

Biological agents have dramatically improved treatment options for patients with severe
psoriasis. Etanercept (tumor necrosis factor [TNF] receptor–immunoglobulin fusion protein) is an …

Background Atopic dermatitis (AD) shows very high prevalence in Asia, with a large unmet
need for effective therapeutics. Direct comparisons between European American (EA) and …

Background Dupilumab is an IL-4 receptor α mAb inhibiting signaling of IL-4 and IL-13, key
drivers of type 2–driven inflammation, as demonstrated by its efficacy in patients with atopic/…

Background Atopic dermatitis (AD) is classified as extrinsic and intrinsic, representing
approximately 80% and 20% of patients with the disease, respectively. Although sharing a similar …

BACKGROUND: In subjects with psoriasis, inflammation and epidermal hyperplasia are
thought to be controlled by T cell–derived cytokines. Evidence suggests that the T H 17 cell …

BACKGROUND: Atopic dermatitis (AD) is a common inflammatory skin disease with a T H 2
and “T22” immune polarity. Despite recent data showing a genetic predisposition to …